Stockscreener 앱 받기
1.58
2.60%
0.04
전일 마감가:
$1.54
열려 있는:
$1.57
하루 거래량:
89,134
Relative Volume:
0.34
시가총액:
$41.21M
수익:
$1.79M
순이익/손실:
$-70.90M
주가수익비율:
-0.1017
EPS:
-15.54
순현금흐름:
$-34.95M
1주 성능:
-5.95%
1개월 성능:
-28.18%
6개월 성능:
-61.93%
1년 성능:
-13.66%
1일 변동 폭
$1.55
$1.6186
1주일 범위
$1.5132
$1.76
52주 변동 폭
$1.5132
$16.94
센티 바이오사이언시스 Stock (SNTI) Company Profile
명칭
Senti Biosciences Inc
전화
(650) 382-3281
주소
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
SNTI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
1.58 | 44.08M | 1.79M | -70.90M | -34.95M | -15.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
센티 바이오사이언시스 Stock (SNTI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-06 | 개시 | Laidlaw | Buy |
| 2022-10-07 | 개시 | Morgan Stanley | Equal-Weight |
센티 바이오사이언시스 주식(SNTI)의 최신 뉴스
Senti Biosciences Inc. stock chart pattern explainedLong-Term Investment Strategy Impact Analysis - Newser
Using data tools to time your Senti Biosciences Inc. exitFree Risk-Adjusted Picks With Exit Strategy - Newser
Momentum divergence signals in Senti Biosciences Inc. chartTechnical Trade Plan with Entry Checklist - Newser
What makes Senti Biosciences Inc. stock price move sharplySecure Asset Flow and Trend Pattern Analysis - Newser
Senti Biosciences: A High-Risk Bet on Biotech's Future? - AInvest
Senti Biosciences completes dose finding in AML therapy trial By Investing.com - Investing.com Australia
Senti Biosciences completes dose finding in AML therapy trial - Investing.com
Senti Bio reports Q2 results, SENTI-202 clinical development advances. - AInvest
Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 - The Manila Times
Senti Bio Advances AML Treatment: Phase 2 Dose Confirmed, FDA Orphan Drug Status Secured - Stock Titan
How Senti Biosciences Inc. stock performs during market volatilityTen-Year Sector Performance and Summary Analysis - Newser
Senti Biosciences shares rise 3.49% premarket after confirming recommended Phase 2 dose for SENTI-202. - AInvest
Tools to assess Senti Biosciences Inc.’s risk profileAnnual Market Behavior and Sector Summary - Newser
Will Senti Biosciences Inc. stock recover after recent dropIn-Depth Stock Trading Volume Analysis - Newser
Is Senti Biosciences Inc. stock overhyped or has real potentialConsistent Gain Plan with AI Support - Newser
Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia - The Manila Times
Breakthrough AML Treatment: Senti Bio's Cell Therapy Shows 67% Complete Remission at Phase 2 Dose - Stock Titan
Senti Biosciences Inc. Forms Double Bottom Pattern — Eyes on BreakoutConsistent Gain Investment Strategies Emerge - metal.it
Is Senti Biosciences Inc. stock entering bullish territoryFree Sector Based Breakout Stock Forecast - Newser
How does Senti Biosciences Inc. generate profit in a changing economyCapitalize on market momentum for maximum gains - Jammu Links News
What are the technical indicators suggesting about Senti Biosciences Inc.Capitalize on market momentum for maximum gains - Jammu Links News
Is Senti Biosciences Inc. stock overvalued or undervaluedFree Stock Market Real-Time Monitoring - Jammu Links News
Why Senti Biosciences Inc. stock attracts strong analyst attentionFast Entry Strategy with Price Prediction - Newser
What catalysts could drive Senti Biosciences Inc. stock higher in 2025High-profit capital plays - Jammu Links News
Is Senti Biosciences Inc. a good long term investmentConsistently outstanding ROI - Jammu Links News
How does Senti Biosciences Inc. compare to its industry peersIdentify undervalued stocks poised to rally - Jammu Links News
What institutional investors are buying Senti Biosciences Inc. stockAchieve breakthrough investment performance - Jammu Links News
How many analysts rate Senti Biosciences Inc. as a “Buy”AI Powered Ideas With High Returns - Jammu Links News
Long term hold vs stop loss in Senti Biosciences Inc.Daily Technical Forecast for Quick Gains - Newser
What is Senti Biosciences Inc. company’s growth strategyEarnings Report Guidance For Smart Trading - Jammu Links News
Is it too late to sell Senti Biosciences Inc.Free Proven Entry Plan With Low Risk Trade - Newser
Senti Biosciences Inc. Recovers — But Is It SustainableTrade Scanner With Buy Zone Alerts Flagged - metal.it
Using Ichimoku Cloud for Senti Biosciences Inc. technicalsMarket Stability and Long-Term Growth Outlook - Newser
Why did SNTI's Q3 2023 earnings fall short of forecasts? - AInvest
Senti Biosciences Inc. Chart Enters High Volatility ZoneLow Risk Swing Trade Opportunities Identified - metal.it
Pattern Scan Adds Senti Biosciences Inc. to WatchlistReal Trader Watchlist of Hot Stocks Released - metal.it
How Efficient Is Senti Biosciences Inc. at Controlling Operating CostsBuy List With Technical Entry Triggers - Newser
Full technical analysis of Senti Biosciences Inc. stock Trade Safety Matrix for Conservative Traders - Newser
Is Senti Biosciences Inc. stock entering bullish territory Free Capital Growth With Controlled Risk Picks - Newser
센티 바이오사이언시스 (SNTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):